Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Luger

Showing results (281-290 of 311) with videos related to

Pageof 32
Sort By:
Leukemia Research|October 30, 2012
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosisAdi Diab, Lynette Zickl, Omar Abdel-Wahab, et al.
Bone Marrow Transplantation|March 29, 2011
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDSS M Luger, O Ringdén, M-J Zhang, et al.
Cancer Discovery|May 16, 2019
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid LeukemiaChristine M McMahon, Timothy Ferng, Jonathan Canaani, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
JAMA Oncology|December 17, 2020
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical TrialAreej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Pageof 32

Showing results (281-290 of 311) with videos related to

Sort By:
Pageof 32
Leukemia Research|October 30, 2012
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosisAdi Diab, Lynette Zickl, Omar Abdel-Wahab, et al.
Bone Marrow Transplantation|March 29, 2011
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDSS M Luger, O Ringdén, M-J Zhang, et al.
Cancer Discovery|May 16, 2019
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid LeukemiaChristine M McMahon, Timothy Ferng, Jonathan Canaani, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
JAMA Oncology|December 17, 2020
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical TrialAreej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Pageof 32